An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension
Keith Owen, David M. Cross, Mazin Derzi, Elizabeth Horsley, Fiona L. StavrosVolume:
64
Année:
2012
Langue:
english
DOI:
10.1016/j.yrtph.2012.05.017
Fichier:
PDF, 225 KB
english, 2012